Mission Therapeutics sells AKI candidate MTX652 to Dimerix in deal worth up to $292 million

The divestment gives Mission non-dilutive capital to advance Parkinson’s drug MTX325, while Dimerix adds a Phase 2-ready renal program with an open U.S. IND cleared by the FDA to proceed.

38d ago